Summary We examined the effect of selective thromboxane A2 (TXA2) receptor antagonists, calcium 5(Z)-iR, 2S, 3S, 4S-7-[3-phenylsulphonylaminobicyclo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) and +-7-(3,5,6,-trimethyl-1,4-benzoquinon-2-yl)-7-phenylhaptanoic acid (AA-2414), on sensitivity to cis-diamminedichloroplatinum (II) (CDDP) in non-small-cell lung cancer cell lines. IC50 values to CDDP using MTT assay were decreased 2.1-and 4.6-fold respectively by treatment with 250 or 500 gM S-1452, for a 2 h simultaneous drug exposure, and those of PC-9/CDDP, a CDDP-resistant cell line, were decreased 3.1-and 6.1-fold. Sensitivity to carboplatin was also enhanced by the treatment with S-1452. IC50 values to CDDP and carboplatin were decreased by treatment with AA-2414 in a dose-dependent manner. Isobologram analysis showed that the combination of CDDP with S-1452 or AA-2414 produced supra-additive or additive effects in each cell line. Neither glutathione content nor glutathione S-transferase activity was changed in either cell line by treatment with 500 gM S-1452. Accumulation of platinum into PC-9 and PC-9/CDDP was increased by the treatment in a dose-dependent manner. Na+, K+-ATPase activity of PC-9 and PC-9/CDDP was enhanced by the treatment of S-1452 in a dose-dependent manner. These data show that the TXA2 receptor antagonists may enhance the sensitivity of non-small-cell lung cancer cell lines to platinum agents. Increase in Na+, K+-ATPase activity induced by S-1452 may be the mechanism of its sensitising effect through increase in platinum accumulation.
Cis-diamminedichloroplatinum (II) (CDDP) is an important anti-cancer agent for the treatment of lung cancer (Loether et al., 1984) that is often limited by the development of resistance. A variety of mechanisms of CDDP resistance have been described , including decreased drug accumulation (Andrews et al., 1988) , increased detoxification by thiol-containing scavenger molecules, such as glutathione (GSH) and metallothionein (Kasahara et al., 1991) , and increased repair of DNA damage (Eastman et al., 1988) . In these investigations resistance mechanism is multifactorial, and one of the mechanisms more commonly observed is an accumulation defect . On the basis of the above mechanisms of resistance, several strategies for overcoming the problem have been proposed. These include the depletion of glutathione (Hromas et al., 1987) , inhibition of DNA repair (Roberts et al., 1986) and increase in CDDP accumulation (Morikage et al., 1993) .
Calcium 5(Z)-1R, 2S, 3S, 4S-7-[3-phenylsulphonylaminobicyclo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) (Dube et al., 1992) , and (± )-7-3(3,5,6,-trimethyl-1,4-benzoquinon-2-yl)-7-phenylhaptanoic acid (AA-2414) (Kurokawa et al., 1994) are selective TXA2 receptor antagonists. In this study, we evaluated the effect of S-1452 and AA-2414 on the sensitivity of non-small-cell lung cancer cell lines to CDDP and carboplatin (CBDCA). There was a sensitising effect of TXA2 receptor antagonists on the cytotoxicity of platinum agents and we examined the mechanism of the sensitising effect of TXA2 receptor antagonists.
Materials and methods
Drugs and chemicals RPMI-1640 and calcium-free and magnesium-free Dulbecco's phosphate-buffered saline (PBS) were purchased from Nissui Pharmaceutical, Tokyo, Japan. CDDP and CBDCA were obtained from the Bristol Myers Squibb, Tokyo, Japan. Calcium 5(Z)-1R, 2S, 3S, 4S-7-[3-phenylsulphonylaminobicyclo [2.2.1] hept-2-yl]-5-heptonoate hydrate (S-1452) ( Figure 1 ) was obtained from the Shionogi, Osaka, Japan and (±)-7- (3, 5, 6 ,-trimethyl-1, 4-benzoquinon -2 -yl) -7 -phenylhaptanoic acid (AA-2414) (Figure 1 ) was obtained from Takeda Chemical Industries, Tokyo, Japan. These antagonists were dissolved in dimethylsulphoxide (DMSO) before use. The maximum concentration of DMSO in each experiment did not exceed 1%, and this concentration of DMSO did not influence drug sensitivity, accumulation or enzyme activities (data not shown). 86Rb as a rubidium chloride and liquid scintillant (ACS II) were purchased from Amersham Japan (Tokyo, Japan). All other drugs and chemicals were purchased from Sigma Chemical Co (St Louis, MO, USA).
Cell lines PC-9 cell line was derived from a human adenocarcinoma of lung and established by Dr Y Hayata, Tokyo Medical College. PC-9/CDDP, a CDDP-resistant cell line, was established and characterised previously . We obtained these cell lines from the Pharmacology Division, National Cancer Center Research Institute, Tokyo. The PC-9/CDDP cell line demonstrated cross-resistance alkylating agents, such as chlorambucil, melphalan and 3-[(4-amino-2-methyl-5-pyrimidinyl)]methyl-1 -(2-chloroethyl)-1 -nitrosourea. The GSH content of PC-9/CDDP cells was increased 3.2-fold compared with PC-9 cells. Treatment with DL-buthionine-S, R-sulphoximine resulted in partial reversal of the resistance. Intracellular accumulation in PC-9/CDDP cells was lower than in PC-9 cells. Fujiwara et al. (1990) have concluded that the increase in GSH content and decrease in drug accumulation might be responsible for the resistance of PC-9/CDDP cells. There is no significant difference in doubling time (24 + 2 h in PC-9 and 26 + 2 h in PC-9/ CDDP) and protein contents (163 + 18 ,ug protein 106 cells in PC-9 and 180±10,Ig protein 106 cells) between these two cell lines. The cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco Laboratories, Grand Island, NY, USA), 100 ,ig ml-1 streptomycin and 100 units ml-' penicillin in a humidified atmosphere of 5% carbon dioxide and 95% air. 
Isobologram analysis
The effect on the IC50 value of TXA2 receptor antagonists combined with platinum agents was analysed by an isobologram method (Steel et al., 1979; Berenbaum, 1989 'Rb+ influx assay
The Na+, K+-ATPase activities in these cell lines were determined by measuring 86Rb+ influx as a marker for K+ influx using the method of Ohmori et al. (1994) . Briefly, the harvested cells were resuspended in Hepes buffer (10 mM glucose, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 10 mM Hepes hydrochloric acid, and 123 mM sodium chloride and adjusted to pH 7.4
with Tris base) at a density of 1 x 106 cells ml-'. The medium was then replaced by 1 ml of Hepes buffer containing 86Rb+
(1 MCi ml-1) preheated at 37°C and mixed by pipetting. To evaluate the effect of S-1452 on 86Rb+ influx, cells were treated with S-1452 (250 or 500 gM) or vehicle for 60 min.
The cell suspension was incubated for various times (1, 5, 10, 20 and 60 min) at 37°C and washed twice with ice-cold PBS. Then, the cell pellets were solubilised with 1 ml of 5% sodium dodecyl sulphate, and 0.9 ml was mixed with 10 ml of ACS II. The radioactivity was counted by liquid scintillation counter. The data were corrected for non-specific absorption of 86Rb+ by subtracting the radioactivity associated with the cells at 4°C. (Table II) . Isobolograms at IC50 were made (Figure 2 ). For simultaneous exposure to CDDP and S-1452, the combined data points fell on the left side of envelope or in the envelope in each cell line (Figure 2a and b) . Figure 2c and d showed the isobologram combined with CDDP and AA-2414. In PC-9, the combined data points fell in the envelope (Figure 2c ) and those of PC-9/CDDP fell on the left side of envelope or in the envelope (Figure 2d ). This indicates that the effect of TXA2 receptor antagonists on the sensitivity to CDDP was supra-additive or additive.
To elucidate the effect of S-1452 on detoxification mechanisms, we measured GSH contents and total GST activities of PC-9 and PC-9/CDDP cells with and without S-1452 treatment. There was no significant change in GSH content or GST activity by treatment with 500 gM S-1452 for 2 h (Table III) .
The kinetics of CDDP accumulation was examined (Figure 3a) . CDDP concentration of 50 gM was chosen for these studies because. it is approximately equal to the IC50 values for PC-9 cells. Accumulation of CDDP increased linearly up to 120 min with or without S-1452 treatment. There was a significant increase in CDDP accumulation in both cell lines by co-incubation with S-1452. After exposure to CDDP for 120 min, we also evaluated efflux of CDDP from PC-9 and PC-9/CDDP cells with or without S-1452 treatment. There was no significant difference in the efflux of CDDP as a function of S-1452 in each cell line. The effect of S-1452 on CDDP accumulation was also dose-dependent (Figure 3b ). S-1452 at 250 and 500 gM resulted in 1.1 and 1.4-fold increase in CDDP accumulation in PC-9 cells, and 1.3-and 1.6-fold increase in PC-9/CDDP cells. Accumulation into PC-9/CDDP treated with S-1452 was approximately equal to that into PC-9 without the treatment.
To elucidate the mechanism of increase in CDDP accumulation by S-1452, we determined 86Rb+ influx as an indicator of Na+, K+-ATPase activity (Figure 4 ). 86Rb+ influx of PC-9/CDDP was decreased compared with that of PC-9. When treated with 250 or 500 MM S-1452, 86Rb+ influx of PC-9 cells was significantly increased 1.3-fold and 1.6-fold respectively. In PC-9/CDDP cells, 86Rb+ influx was significantly increased on the treatment by 1.2-fold and 1.5-fold respectively. The increase in 16Rb± influx in each cell line was correlated with platinum accumulation (P<0.01). (1990) have reported that GSH depletion by DL-buthionine-S, R-sulphoximine induced a 1.8-fold increase in the sensitivity of PC-9 and PC-9/CDDP. Ethacrynic acid, a specific inhibitor of GST, has also induced increase in the sensitivity (Kasahara et al., 1991). Pentoxifylline has also been shown to increase anti-tumour activity of CDDP (Schiano et al., 1991) . These studies suggested the importance of trying to improve present chemotherapy by enhancing its effect with other chemical agents, as well as attempting to develop new agents.
In this study we evaluated the effect of TXA2 receptor antagonists, S-1452 and AA-2414, on the sensitivities of two non-small-cell lung cancer cell lines to CDDP and CBDCA. These are highly potent and selective antagonists for the TXA2 receptor (Dube et al., 1992; Kurokawa et al., 1994) . Treatment with S-1452 or AA-2414 decreased IC50 value to CDDP and CBDCA in PC-9 and PC-9/CDDP cells (Tables I  and II) . Isobologram analysis showed that CDDP had a supra-additive or additive effect when combined with S-1452 or AA-2414 (Figure 2 ). These studies demonstrate that TXA2 receptor antagonists affect sensitivity to CDDP and CBDCA.
To evaluate the mechanism(s) of the effect of S-1452 on the sensitivity to platinum agents, we measured GSH content, GST activity and platinum accumulation in PC-9 and PC-9/ CDDP. S-1452 had no effect on GSH content and GST activity of PC-9 and PC-9/CDDP cells (Table III) . These data showed that the sensitising effect of S-1452 did not correlate with the GSH content or GST activity. S-1452 increased the platinum accumulation into PC-9 and PC-9/CDDP. An increase in platinum accumulation was dependent on the concentration of S-1452 and related to the increase in sensitivity to CDDP (Figure 3 ). There was a 40% increase in platinum accumulation in PC-9 cells and 60% in PC-9/ CDDP cells when treated with 500 giM S-1452. Because kinetic study showed that there was no difference in the efflux of platinum from PC-9 and PC-9/CDDP cells, the increase in influx may result in increase in accumulation. The increase in platinum influx may explain the S-1452 sensitising effect. To elucidate the mechanism of increase in uptake, we evaluated the Na+, K+-ATPase activity indicated as a 86Rb+ influx rate and the effect of the S-1452 (Figure 4) . Na+, K+-ATPase activity of PC-9/CDDP was decreased compared with that of PC-9. This decrease in Na+, K+-ATPase activity may explain the decrease in CDDP accumulation in PC-9/ CDDP. Treatment with S-1452 resulted in an increase in the Na+, K+-ATPase activity in a dose-dependent manner. This increase may be responsible for the increase in platinum accumulation and sensitising effect of TXA2 receptor antagonists.
The mechanism by which CDDP enters tumour cells remains unknown. It has been postulated that CDDP enters the cells by passive diffusion (Mann et al., 1990) . However, many studies showed that CDDP accumulation could be specifically stimulated and inhibited by pharmacological agents (Oates et al., 1988) . Nigam et al. (1985) have proposed that 6-keto-prostaglandin Fic. (an inactive metabolite of prostaglandin 12/TXB2 ratio might be an indicator for tumour growth and metastasis. TXA2 has also been shown to play an important role in tumour proliferation (Nigam et al., 1990) . Ushikubi et al. (1993) have reported that treatment with a TXA2 agonist, 9,1 1-epithio-l 1,12-methano-thromboxane A2, caused DNA fragmentation in thymocytes, and this change was blocked by S-1452 S- . Teicher et al. (1994 have reported that cyclooxygenase inhibitors enhance cytotoxicity of CDDP in vivo. These data suggest that TXA2 and TXA2 receptor may be relevant to cancer cell growth, apoptosis and cell death. In this study, TXA2 receptor antagonists showed additive or synergistic effect when combined with CDDP. TXA2 receptor antagonists used in our study might have some effect on cell cycle or apoptosis and these effects might result in a synergistic effect of TXA2 receptor antagonists when combined with CDDP.
In conclusion, TXA2 receptor antagonists decreased the IC50 value to CDDP and CBDCA in non-small-cell lung cancer cell lines. This effect was supra-additive or additive. An increase in platinum accumulation owing to increased Na+, K+-ATPase may be responsible for the enhanced efficacy of platinum. Our data suggest that TXA2 receptor antagonists, such as S-1452 or AA-2414, may have a role in enhancing CDDP-based chemotherapy for lung cancer.
